Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Non Operating Income (2022 - 2025)

Atara Biotherapeutics' Non Operating Income history spans 4 years, with the latest figure at -$843000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 847.19% year-over-year to -$843000.0; the TTM value through Dec 2025 reached -$3.1 million, down 14866.67%, while the annual FY2025 figure was -$3.1 million, 695.27% down from the prior year.
  • Non Operating Income reached -$843000.0 in Q4 2025 per ATRA's latest filing, down from -$701000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $50.6 million in Q2 2022 to a low of -$843000.0 in Q4 2025.
  • Average Non Operating Income over 4 years is $3.0 million, with a median of -$143000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: skyrocketed 372.06% in 2024, then crashed 13350.0% in 2025.
  • A 4-year view of Non Operating Income shows it stood at $969000.0 in 2022, then crashed by 149.23% to -$477000.0 in 2023, then soared by 81.34% to -$89000.0 in 2024, then tumbled by 847.19% to -$843000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Non Operating Income are -$843000.0 (Q4 2025), -$701000.0 (Q3 2025), and -$807000.0 (Q2 2025).